99 related articles for article (PubMed ID: 19039062)
1. Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.
Rossignol DP; Wong N; Noveck R; Lynn M
Innate Immun; 2008 Dec; 14(6):383-94. PubMed ID: 19039062
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.
Rossignol DP; Wasan KM; Choo E; Yau E; Wong N; Rose J; Moran J; Lynn M
Antimicrob Agents Chemother; 2004 Sep; 48(9):3233-40. PubMed ID: 15328078
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue.
Rossignol DP; Lynn M
J Endotoxin Res; 2002; 8(6):483-8. PubMed ID: 12697095
[TBL] [Abstract][Full Text] [Related]
4. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia.
Lynn M; Rossignol DP; Wheeler JL; Kao RJ; Perdomo CA; Noveck R; Vargas R; D'Angelo T; Gotzkowsky S; McMahon FG
J Infect Dis; 2003 Feb; 187(4):631-9. PubMed ID: 12599080
[TBL] [Abstract][Full Text] [Related]
5. Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected].
Lynn M; Wong YN; Wheeler JL; Kao RJ; Perdomo CA; Noveck R; Vargas R; D'Angelo T; Gotzkowsky S; McMahon FG; Wasan KM; Rossignol DP
J Pharmacol Exp Ther; 2004 Jan; 308(1):175-81. PubMed ID: 14566003
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
Mullarkey M; Rose JR; Bristol J; Kawata T; Kimura A; Kobayashi S; Przetak M; Chow J; Gusovsky F; Christ WJ; Rossignol DP
J Pharmacol Exp Ther; 2003 Mar; 304(3):1093-102. PubMed ID: 12604686
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function.
Liang E; Wong YN; Allen I; Kao R; Marino M; DiLea C
J Clin Pharmacol; 2003 Dec; 43(12):1361-9. PubMed ID: 14615472
[TBL] [Abstract][Full Text] [Related]
9. E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes.
Czeslick E; Struppert A; Simm A; Sablotzki A
Inflamm Res; 2006 Nov; 55(11):511-5. PubMed ID: 17122970
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study.
Wong YN; Rossignol D; Rose JR; Kao R; Carter A; Lynn M
J Clin Pharmacol; 2003 Jul; 43(7):735-42. PubMed ID: 12856387
[TBL] [Abstract][Full Text] [Related]
11. In vivo Toll-like receptor 4 antagonism restores cardiac function during endotoxemia.
Ehrentraut S; Lohner R; Schwederski M; Ehrentraut H; Boehm O; Noga S; Langhoff P; Baumgarten G; Meyer R; Knuefermann P
Shock; 2011 Dec; 36(6):613-20. PubMed ID: 22089127
[TBL] [Abstract][Full Text] [Related]
12. A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.
Bennett-Guerrero E; Grocott HP; Levy JH; Stierer KA; Hogue CW; Cheung AT; Newman MF; Carter AA; Rossignol DP; Collard CD
Anesth Analg; 2007 Feb; 104(2):378-83. PubMed ID: 17242095
[TBL] [Abstract][Full Text] [Related]
13. LPS binding protein does not participate in the pharmacokinetics of E5564.
Kaneko K; Ueda R; Kawata T; Ishizaka S; Yoshimura T
J Endotoxin Res; 2004; 10(3):185-94. PubMed ID: 15198853
[TBL] [Abstract][Full Text] [Related]
14. Effects of eritoran tetrasodium, a toll-like receptor 4 antagonist, on intestinal microcirculation in endotoxemic rats.
Yeh YC; Ko WJ; Chan KC; Fan SZ; Tsai JC; Cheng YJ; Sun WZ
Shock; 2012 May; 37(5):556-61. PubMed ID: 22392144
[TBL] [Abstract][Full Text] [Related]
15. Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits.
Wasan KM; Risovic V; Sivak O; Lee SD; Mason DX; Chiklis GR; McShane J; Lynn M; Wong N; Rossignol DP
Pharm Res; 2008 Jan; 25(1):176-82. PubMed ID: 17849177
[TBL] [Abstract][Full Text] [Related]
16. Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteins.
Fleischer JG; Rossignol D; Francis GA; Chan T; Lynn M; Wasan KM
Innate Immun; 2012 Feb; 18(1):171-8. PubMed ID: 21382909
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran.
Kim HM; Park BS; Kim JI; Kim SE; Lee J; Oh SC; Enkhbayar P; Matsushima N; Lee H; Yoo OJ; Lee JO
Cell; 2007 Sep; 130(5):906-17. PubMed ID: 17803912
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide.
Savov JD; Brass DM; Lawson BL; McElvania-Tekippe E; Walker JK; Schwartz DA
Am J Physiol Lung Cell Mol Physiol; 2005 Aug; 289(2):L329-37. PubMed ID: 15833764
[TBL] [Abstract][Full Text] [Related]
19. In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands.
de Vos AF; Pater JM; van den Pangaart PS; de Kruif MD; van 't Veer C; van der Poll T
J Immunol; 2009 Jul; 183(1):533-42. PubMed ID: 19542464
[TBL] [Abstract][Full Text] [Related]
20. A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia.
Bunnell E; Lynn M; Habet K; Neumann A; Perdomo CA; Friedhoff LT; Rogers SL; Parrillo JE
Crit Care Med; 2000 Aug; 28(8):2713-20. PubMed ID: 10966240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
